Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) EBT Margin (2016 - 2025)

Regen BioPharma (RGBP) has disclosed EBT Margin for 11 consecutive years, with 964.31% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 50824.0% to 964.31% in Q3 2025 year-over-year; TTM through Sep 2025 was 538.76%, a 21923.0% decrease, with the full-year FY2025 number at 538.76%, down 25627.0% from a year prior.
  • EBT Margin was 964.31% for Q3 2025 at Regen BioPharma, down from 283.23% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 13.48% in Q3 2021 to a low of 1520.94% in Q4 2022.
  • A 5-year average of 352.08% and a median of 220.3% in 2024 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -107394bps in 2022, then surged 127556bps in 2023.
  • Regen BioPharma's EBT Margin stood at 447.0% in 2021, then tumbled by -240bps to 1520.94% in 2022, then surged by 84bps to 245.38% in 2023, then tumbled by -256bps to 872.57% in 2024, then dropped by -11bps to 964.31% in 2025.
  • Per Business Quant, the three most recent readings for RGBP's EBT Margin are 964.31% (Q3 2025), 283.23% (Q2 2025), and 32.77% (Q1 2025).